The "growth or progress of the brand", as you say, fails to impress me without collateral revenues to support the premise. You can wax eloquent as you please, but the real money will come into this play only with verifiable revenues, not anecdotal evidence. In the meantime, I will play the PR induced swings just as HighAspirations does. Falling in love with an OTC issue is fools play.